biostudies-literatureChen YScience Foundation of the Postdoctoral Department of Heilongjiang ProvinceProgram of Science and Technology of Sichuan ProvinceHaiyan Research Funding of the Harbin Medical University Cancer Hospital11https://www.ebi.ac.uk/biostudies/studies/S-EPMC9875443biostudies-literatureUnknown11(1)BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPorBiomarker researchThe clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses.PMC9875443JJZD2021-032021YFQ0037LBH-Q21118Wu MLin THuang HZhang HWu CMa YGu ALiang CLiu YOu QE MShao YZhang YYe SGuo HWeng HChen YPu XChen XSun HDeng YWu XfalseThe clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses.BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPor2023-01-01T00:00:00Z2023 Jan2026-05-29T05:32:59.256Z2025-02-18T23:45:00.211ZS-EPMC98754433669423110.1186/s40364-022-00443-8